Marion McCourt - Feb 1, 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Commercial
Signature
/s/**Marion McCourt
Stock symbol
REGN
Transactions as of
Feb 1, 2023
Transactions value $
-$417,703
Form type
4
Date filed
2/3/2023, 03:13 PM
Previous filing
Jan 5, 2023
Next filing
Feb 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $410K +1.1K +4.98% $372.46 23.2K Feb 1, 2023 Direct F1
transaction REGN Common Stock Sale -$827K -1.1K -4.75% $752.19 22.1K Feb 1, 2023 Direct F1
holding REGN Common Stock 138 Feb 1, 2023 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -1.1K -12.57% $0.00 7.65K Feb 1, 2023 Common Stock 1.1K $372.46 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.